Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676148 | 0.80 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12862673 | 0.80 | — | — | |
| SCHEMBL20738716 | 0.80 | — | — | |
| SCHEMBL13567235 | 0.80 | — | — | |
| SCHEMBL18793690 | 0.80 | NOS1 (0.31) | — | |
| SCHEMBL11292151 | 0.77 | NPC1 (0.30) | ALDH1A1HPGDNPC1TP53MAPT | |
| SCHEMBL14226108 | 0.77 | TLR8 (0.33) | — | |
| SCHEMBL17045369 | 0.75 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL16877173 | 0.75 | — | — | |
| SCHEMBL11818046 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| WO-2023230038-A1 | PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023110869-A1 | MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | ALDH1A1 640/4885HPGD 835/4885NPC1 1907/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | ALDH1A1 2627/4885HPGD 1298/4885NPC1 3375/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | ALDH1A1 3814/4885HPGD 1351/4885NPC1 1058/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | ALDH1A1 3535/4885HPGD 1575/4885NPC1 1566/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885HPGD 1759/4885NPC1 2241/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | ALDH1A1 1943/4885HPGD 139/4885NPC1 461/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885HPGD 546/4885NPC1 275/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ALDH1A1 1779/4885HPGD 3777/4885NPC1 245/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | ALDH1A1 2326/4885HPGD 2873/4885NPC1 1062/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | ALDH1A1 640/4885HPGD 835/4885NPC1 1907/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | ALDH1A1 3268/4885HPGD 4109/4885NPC1 2128/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | ALDH1A1 3879/4885HPGD 1386/4885NPC1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.